Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Master Protocol Study of DCC-3084 in Advanced MAPK Pathway–Driven Solid Tumors
2024-517829-12-00Phase 2Completed
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of dcc-3084 in Nonhematologic neoplasms, sponsored by Deciphera Pharmaceuticals. Primary endpoints: Number of participants with dose-limiting toxicities (DLTs) - Part 1 and Objective response rate (ORR) - Part 2. Started Jun 2025; status: completed.
02
Drugs
dcc-3084
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-517829-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517829-12-00.